Your browser doesn't support javascript.
loading
Drugs targeting adenosine signaling pathways: A current view.
Kutryb-Zajac, Barbara; Kawecka, Ada; Nasadiuk, Khrystyna; Braczko, Alicja; Stawarska, Klaudia; Caiazzo, Elisabetta; Koszalka, Patrycja; Cicala, Carla.
Afiliação
  • Kutryb-Zajac B; Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland. Electronic address: b.kutryb-zajac@gumed.edu.pl.
  • Kawecka A; Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Nasadiuk K; Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Braczko A; Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Stawarska K; Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Caiazzo E; Department of Pharmacy, School of Medicine, University of Naple Federico II, 80131 Naples, Italy.
  • Koszalka P; Laboratory of Cell Biology and Immunology, Institute of Medical Biotechnology and Experimental Oncology, Intercollegiate Faculty of Biotechnology University of Gdansk and Medical University of Gdansk, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Cicala C; Department of Pharmacy, School of Medicine, University of Naple Federico II, 80131 Naples, Italy.
Biomed Pharmacother ; 165: 115184, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37506580
Adenosine is an endogenous nucleoside that regulates many physiological and pathological processes. It is derived from either the intracellular or extracellular dephosphorylation of adenosine triphosphate and interacts with cell-surface G-protein-coupled receptors. Adenosine plays a substantial role in protecting against cell damage in areas of increased tissue metabolism and preventing organ dysfunction in pathological states. Targeting adenosine metabolism and receptor signaling may be an effective therapeutic approach for human diseases, including cardiovascular and central nervous system disorders, rheumatoid arthritis, asthma, renal diseases, and cancer. Several lines of evidence have shown that many drugs exert their beneficial effects by modulating adenosine signaling pathways but this knowledge urgently needs to be summarized, and most importantly, actualized. The present review collects pharmaceuticals and pharmacological or diagnostic tools that target adenosine signaling in their primary or secondary mode of action. We overviewed FDA-approved drugs as well as those currently being studied in clinical trials. Among them are already used in clinic A2A adenosine receptor modulators like istradefylline or regadenoson, but also plenty of anti-platelet, anti-inflammatory, or immunosuppressive, and anti-cancer drugs. On the other hand, we investigated dozens of specific adenosine pathway regulators that are tested in clinical trials to treat human infectious and noninfectious diseases. In conclusion, targeting purinergic signaling represents a great therapeutic challenge. The actual knowledge of the involvement of adenosinergic signaling as part of the mechanism of action of old drugs has open a path not only for drug-repurposing but also for new therapeutic strategies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Adenosina / Trifosfato de Adenosina Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Adenosina / Trifosfato de Adenosina Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2023 Tipo de documento: Article